These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P; Hassard S; Newman JF; Brown F Vaccine; 1995; 13(8):781-4. PubMed ID: 7483796 [TBL] [Abstract][Full Text] [Related]
24. Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera. Schiappacassi M; Rieder Rojas E; Carrillo E; Campos R Virus Res; 1995 Apr; 36(1):77-85. PubMed ID: 7542827 [TBL] [Abstract][Full Text] [Related]
25. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Kitson JD; McCahon D; Belsham GJ Virology; 1990 Nov; 179(1):26-34. PubMed ID: 1699353 [TBL] [Abstract][Full Text] [Related]
26. Protection conferred by TrpE fusion proteins containing portions of the C-terminal region of capsid protein VP1 of foot-and-mouth disease virus. Giavedoni LD; Kaplan G; Marcovecchio F; Piccone ME; Palma EL J Gen Virol; 1991 Apr; 72 ( Pt 4)():967-71. PubMed ID: 1849980 [TBL] [Abstract][Full Text] [Related]
27. Characterization of the structural-protein-coding region of SAT 2 type foot-and-mouth disease virus. van Rensburg HG; Nel LH Virus Genes; 1999; 19(3):229-33. PubMed ID: 10595414 [TBL] [Abstract][Full Text] [Related]
28. Genetic and antigenic analysis of type A foot-and-mouth disease viruses isolated in India during 1987-1996. Nayak B; Pattnaik B; Tosh C; Sanyal A; Hemadri D; Patil SS; Venkataramanan R Acta Virol; 2001 Feb; 45(1):13-21. PubMed ID: 11394573 [TBL] [Abstract][Full Text] [Related]
29. Characteristic in vitro evolution pattern of foot and mouth disease virus A81/Castellanos/Arg/87. Mbayed V; Schiappacassi M; Corominas A; Campos R Virus Res; 1997 May; 48(2):157-63. PubMed ID: 9175254 [TBL] [Abstract][Full Text] [Related]
30. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Wong HT; Cheng SC; Chan EW; Sheng ZT; Yan WY; Zheng ZX; Xie Y Virology; 2000 Dec; 278(1):27-35. PubMed ID: 11112477 [TBL] [Abstract][Full Text] [Related]
31. Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites. Mateu MG; Hernández J; Martínez MA; Feigelstock D; Lea S; Pérez JJ; Giralt E; Stuart D; Palma EL; Domingo E J Virol; 1994 Mar; 68(3):1407-17. PubMed ID: 8107204 [TBL] [Abstract][Full Text] [Related]
32. Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes. Kit M; Kit S; Little SP; Di Marchi RD; Gale C Vaccine; 1991 Aug; 9(8):564-72. PubMed ID: 1722936 [TBL] [Abstract][Full Text] [Related]
33. A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice. Zamorano P; Wigdorovitz A; Perez-Filgueira M; Carrillo C; Escribano JM; Sadir AM; Borca MV Virology; 1995 Oct; 212(2):614-21. PubMed ID: 7571431 [TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus. Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367 [TBL] [Abstract][Full Text] [Related]
35. [Synthesis and immunogenic properties of peptides--fragments of the immunodominant regions of the VP1 protein of the Asia-1 type of foot- and-mouth disease virus]. Petrov VN; Rybakov SS; Petrova ON; Chepurkin AV; Gulenkin VM Bioorg Khim; 1998 Dec; 24(12):899-905. PubMed ID: 10079947 [TBL] [Abstract][Full Text] [Related]
36. Antigenic variation in Foot and Mouth Disease Virus type Asia 1 isolates circulated during 1993-95 in India. Tulasiram P; Tyagi M; Srinivas K; Prabhudas K; Natarajan C; Suryanarayana V Virus Genes; 1997; 15(3):247-53. PubMed ID: 9482590 [TBL] [Abstract][Full Text] [Related]
37. Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP1. Doel TR; Gale C; Brooke G; DiMarchi R J Gen Virol; 1988 Sep; 69 ( Pt 9)():2403-6. PubMed ID: 2457649 [TBL] [Abstract][Full Text] [Related]
38. Extensive antigenic diversification of foot-and-mouth disease virus by amino acid substitutions outside the major antigenic site. Feigelstock D; Mateu MG; Piccone ME; De Simone F; Brocchi E; Domingo E; Palma EL J Gen Virol; 1992 Dec; 73 ( Pt 12)():3307-11. PubMed ID: 1335031 [TBL] [Abstract][Full Text] [Related]
39. Protection against viral infections with the aid of synthetic peptides. Foot-and-mouth disease as an example. Vol'pina OM; Surovoi AYu ; Ivanov VT Biomed Sci; 1990 Jan; 1(1):23-32. PubMed ID: 1718462 [TBL] [Abstract][Full Text] [Related]
40. Protective immune response to 16 kDa immunoreactive recombinant protein encoding the C-terminal VP1 portion of Foot and Mouth Disease Virus type Asia 1. Bayry J; Prabhudas K; Gopalakrishna S; Patil PK; Ramakrishna C; Misra LD; Suryanarayana VV Microbiol Immunol; 1999; 43(8):765-71. PubMed ID: 10524794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]